Public Plan Drug Negotiations Could Stifle Innovation, J&J Testifies

While the presence of a public plan in the health care reform debate has been a source of controversy on its own, the pharmaceutical industry has additional cause for alarm because of language in a draft bill that would give the government responsibility for negotiating drug prices for the public plan